May 19th, 2013

Introducing The Rowboat
Quite Possibly The Holy Grail of Investing.

Step 1: Sell the Put
( This is a Cash Covered Put, I have to have enough Cash to buy 100 shares per contract if the option is exercised, this is also my maximum risk.)
SCTY @ $45.00

Sell To Open SCTY June 2013 $35.00 Put @ Market
Currently $2.65 bid / $2.75 time

7.57% return in 32 days

How to do this trade and commentary Video:

(Sign up for Auto-trading and have this trade done for you automatically)

http://youtu.be/DJx6apt_Tx4

SolarCity Corporation engages in the design, installation, and sale or
lease of solar energy systems to residential and commercial
customers, and government entities in the United States. It provides
solar energy systems; and energy efficiency products and services,
including home energy evaluation, and energy efficiency upgrade
products and services. The company also sells electricity generated by

solar energy systems to customers. In addition, it markets and installs
electric vehicle charging equipment to residential and commercial
customers through retail partnerships. The company was founded in
2006 and is headquartered in San Mateo, California.
SolarCity Corporation
3055 Clearview Way

San Mateo, CA 94402
Phone: 650-638-1028
Fax: 650-638-1029
Website: http://www.solarcity.com
News:
http://www.fool.com/investing/general/2013/05/18/this-week-in-solar-10.aspx

Remember, no more than 5 or 10% of your portfolio should ever go
into any one trade or position.

Step 2: IFit got Put to us, Now we “Lock-in” a profit.
Sell theCovered Call
(Do not buy a stock just to sell the covered Call)
Nothing got “Put” to us.
How to do this trade and commentary Video:
(Sign up for Auto-trading and have this trade done for you automatically)

Remember, no more than 5 or 10% of your portfolio should ever go

into any one trade or position.
How did we do last Month?

UNXL @ $27.19
Uni-Pixel, Inc.
Put expired, move to closed positions
11.75% Return in 3 months
History:
Cost basis $20.00 per share.
Premiums collected: $2.35 per share
11.75% Return in 3 months
$10,000 would have generated $1175.00
actual trades:
04/22/2013 Sell To Open UNXL May13 $20 Put $0.55
Previous
03/18/2013 Sell To Open UNXL Apr13 22.5 Put $1.40
Previous
02/19/2013 Sell To Open UNXL Mar13 $15 Put $0.40

Current/Older Positions/History

This includes a running total for each open position.
Do not enter these positions.

CLSN @ $1.01

Celsion Corporation

Put to us @ $2.00

Hold

No good options at this time.
Be patient, it will bounce back.
The insiders and the sharks are buying.

Earnings date: August 9th

History:

Cost basis $2.00 per share. Premiums collected: $.50 per share 25% Return in 3 months

$10,000 would have generated $2500.00

actual trades:

02/19/2013 Sell To Open CLSN July 2013 $3 Call

(did not fill, because of Holiday) 0.00

02/15/2013 Buy CLSN – Option Assignment $2.00 01/22/2013 Sell To Open CLSN Feb13 2 Put $0.30 12/24/2012 Sell To Open CLSN Jan13 2 Put $0.20

Celsion Corporation, an oncology drug development company, engages in the development and commercialization of targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company develops ThermoDox, a liposomal encapsulation of doxorubicin, which is under Phase III clinical trial for primary liver cancer; under phase II clinical trial for colorectal liver metastasis; and under phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. for ThermoDox; a license agreement with Duke University to commercialize and use Duke’s thermo-liposome technology; and a joint research agreement with Royal Philips Electronics to evaluate the combination of Philips’ high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat various cancers. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

Celsion Corp.

997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
Phone: 609-896-9100
Fax: 609-896-2200

Website: http://www.celsion.com

News:

http://seekingalpha.com/article/1329651-3-biotechs-and-the-feuerstein-ratain-rule

DMND @ $16.70

Put to us @ $32.00

Hold

No good options at this time

3.59% Return

History:

Cost basis $32.00 per share. Premiums collected: 1.15 per share 3.59% Return in 14 months

$10,000 would have generated $359.00

actual trades:

09/24/2012 Sell To Open DMND Dec12 30 Call $0.20 03/20/2012 Sell To Open DMND Jun12 33 Call $0.25 03/18/2012 Buy To Close EXPIRED DMND Mar12 32 CALL 02/21/2012 Sell To Open DMND Mar12 32 Call $0.20 02/17/2012 Buy DMND – Option Assignment $32.00 02/17/2012 Buy To Close DMND Feb12 32 Put 02/06/2012 Sell To Open DMND Feb12 32 Put $1.50

Diamond Foods, Inc. engages in processing, marketing, and distributing snack products. It provides snack products, including roasted, glazed and flavored nuts, trail mixes, dried fruit, seeds, microwave popcorn products, and potato and tortilla chips under the Emerald, Pop Secret, and Kettle brands. The company also offers culinary, in-shell, and ingredient nuts under the Diamond of California brand name. It markets its culinary nuts to individuals who prepare meals or baked goods at home; and ingredient nuts to food processors, restaurants, bakeries, and food service companies and their suppliers. The company sells its products directly to national grocery, mass merchandiser, clubs, convenience stores, and drug store chains in the United States, the United Kingdom, Germany, the Netherlands, Spain, Canada, South Korea, Turkey, China, and Japan. Diamond Foods, Inc. was founded in 1912 and is based in San Francisco, California.

Diamond Foods, Inc.

600 Montgomery Street 13th Floor

San Francisco, CA 94111-2702 Phone: 415-445-7444

Website: http://www.diamondfoods.com

News:

http://seekingalpha.com/article/1270231-diamond-in-the-rough-part-iii-post-earnings?

ELN @ $11.67

Hold: July 2013 $13 Call is still cooking

History:

Cost basis $12.00 per share. Premiums collected: $1.80 per share 15.% Return in 10 months

$10,000 would have generated $1541.00

actual trades:

04/22/2013 Sell To Open ELN Jul13 13 Call $0.05

01/22/2013 Sell To Open ELN Apr13 12 Call $0.10

10/22/2012 Sell To Open ELN Jan13 14 Call $0.10

08/20/2012 Sell To Open ELN Oct12 13 Call $0.35

07/23/2012 Sell To Open ELN Aug12 12 Put $1.20

Elan shareholders on the register on December 14, 2012, the record date, received 1 Prothena (PRTA) ordinary share for every 41 Elan ordinary shares or ADSs held.

PRTA @ $9.86

Elan Corporation, plc operates as a neuroscience-based biotechnology company in the United States, Ireland, and internationally. It engages in research, development, and commercial activities primarily in the areas of Alzheimer s disease, Parkinson s disease, and multiple sclerosis (MS). The company offers Tysabri, an alpha-4 integrin inhibitor primarily for the treatment of MS. It is also developing ELND005, a beta amyloid anti- aggregation agent to treat Alzheimer s disease, which completed Phase II clinical trial. In addition, the company focuses on the discovery and development of antibodies to neo-epitope related targets for the treatment of a range of indications, including amyloidosis, diabetes, cancer, and macular degeneration; and drugs for oncology related diseases comprising NEOD001 for the treatment of AL amyloidosis, as well as focuses on developing ELND005 for bipolar disorder. Further, the company, through collaboration agreement with Biogen Idec, Inc., develops and markets Tysabri for the treatment for Crohn s disease. Additionally, Elan Corporation, plc, through a 49.9% interest in Janssen AI, develops beta amyloid immunotherapies, including bapineuzumab, ACC-001, and other compounds to treat Alzheimer s disease.

The company also has collaboration agreements with Cambridge-Elan Centre, Dublin Neurological Institute, University College Dublin, and Proteostasis. Elan Corporation, plc was founded in 1969 and is headquartered in Dublin, Ireland.

Elan Corporation, plc

Treasury Building

Lower Grand Canal Street

Dublin, 2

Ireland

Phone: 353 1 709 4000

Fax: 353 1 709 4700

Website: http://www.elan.com

news

http://finance.yahoo.com/news/elan-royalty-deal-thrx-200003072.html

FMCN @ $27.38

Focus Media Holding Ltd

Correction: Was NOT called away last month.

FMCN May 2013 $27 Called away Move too closed positions

23.33% Return

Current bid on the buy out is $27.50

History:

Cost basis $ 24.00 per share.

Premiums collected: $ 2.60 per share Capital Gain: $3.00

23.33% Return in 13 months

$10,000 would have generated $1791.00

05/17/2013 Sell FMCN – Option Assignment $27.00

04/22/2013 Sell To Open FMCN May13 $27 Call $0.30

01/22/2013 Sell To Open FMCN Apr13 26 Call $0.10

10/22/2012 Sell To Open FMCN Jan13 27 Call $0.20

08/14/2012 Buy To Close FMCN Oct12 27 Call -$0.50

07/23/2012 Sell To Open FMCN Oct12 27 Call $0.40
05/21/2012 Sell To Open FMCN Jul12 27 Call$0.40
04/23/2012 Sell To Open FMCN May12 27 Call $0.45
04/20/2012 Buy FMCN – Option Assignment$24.00
04/20/2012 Buy To Close FMCN Apr12 24 Put
03/19/2012 Sell To Open FMCN Apr12 24 Put $1.15

Focus Media Holding Limited, a multi-platform digital media company, operates liquid crystal display (LCD) network using audiovisual digital displays in China. The company engages in selling out-of-home advertising time slots on its network of flat-panel digital advertising displays located in high traffic areas of commercial, residential, and public buildings, such as malls, hotels, and the lobbies of apartment buildings, as well as in-store network. It provides advertising services on poster frames, on screens in movie theatres, and on traditional outdoor billboards. As of December 31, 2011, the company had a LCD display network of approximately 155,751 flat-panel digital displays in approximately 114 cities; in-store network of approximately 50,076 LCD displays in approximately 1,576 hypermarkets, 217 supermarkets, and 1,008 convenience stores; poster frame network of approximately 445,126 non-digital frames and LCD 1.0 picture frame devices, as well as leased screen time in approximately 316 movie theaters, including 2,190 screens. Focus Media Holding Limited is headquartered in Central, Hong Kong.

News:

http://seekingalpha.com/article/1167761-6-high-growth-bric-small-and-mid-caps-with-bullish-short-trends?

ONTY @ $1.99

HOLD June 2013 $5 Call is still cooking

History:

Cost basis $5.00 per share. Premiums collected: 2.20 per share 44% Return in 16 months

$10,000 would have generated $4300.00

actual trades:

03/18/2013 Sell To Open ONTY Jun13 5 Call $0.05
11/19/2012 Sell To Open ONTY Jan13 6 Call $0.55
05/21/2012 Sell To Open ONTY Nov12 7 Call $0.05
03/20/2012 Sell To Open ONTY May12 6 Call $0.05
03/16/2012 Buy ONTY – Option Assignment $5.00

02/21/2012 Sell To Open ONTY Mar12 $5 Put $0.70
02/19/2012 Buy To Close EXPIRED ONTY FEB12 $5 PUT
01/30/2012 Sell To Open ONTY Feb12 5 Put $0.50
01/22/2012 Buy To Close EXPIRED ONTY JAN12 $5 PUT
01/09/2012 Sell To Open ONTY Jan12 5 Put $0.30

Oncothyreon Inc.(ONTY), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. The company also develops PX-866, a small molecule that is in Phase II trials. In addition, it engages in the preclinical development of ONT-10, a cancer vaccine. The company operates in Canada, the United States, Barbados, and Europe. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

Oncothyreon Inc

2601 Fourth Avenue Suite 500

Seattle, WA 98121 Phone: 206-801-2100 Fax: 206-801-2101
Website: http://www.oncothyreon.com

News:

http://finance.yahoo.com/news/oncothyreon-slumps-cancer-drug-data-155446513.html

PAAS @ $11.74

Hold

there are no good options at this time.

History:

Cost basis $36.00 per share.

Premiums collected: $3.50 per share
Dividends : .23c

Total: $3.73

10.36% Return in 24 months
$10,000 would have generated $1036.00

actual trades:

03/19/2013 PAAS – PAAS QUALIFIED DIVIDEND .125

12/04/2012 PAAS – PAAS QUALIFIED DIVIDEND .125

09/24/2012 Sell To Open PAAS Jan13 40 Call $0.05
01/30/2012Sell To Open PAAS Jul12 36 Call $0.20
12/06/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025
10/24/2011 Sell To Open PAAS Jan12 36 Call $0.40
10/22/2011 Buy To Close EXPIRED PAAS Oct11 36 Call
09/08/2011 PAAS – PAAS QUALIFIED DIVIDEND $.025
06/20/2011 Sell To Open PAAS Oct11 36 Call $0.80
06/19/2011 Buy To Close EXPIRED PAAS JUN11 36 CALL
06/16/2011 PAAS QUALIFIED DIVIDEND $.025
05/23/2011 Sell To Open PAAS Jun11 36 Call $0.50
05/20/2011 Buy PAAS – Option Assignment $36.00
05/20/2011 Buy To Close PAAS May11 36 Put $0.00
04/18/2011 Sell To Open PAAS May11 36 Put $1.55

Pan American Silver Corp. engages in the exploration, development, extraction, processing, production, refining, reclamation, and operation of silver properties. The company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Pan American Silver Corp.

625 Howe Street Suite 1500
Vancouver, BC V6C 2T6 Phone: 604-684-1175 Fax: 604-684-0147

Website: http://www.panamericansilver.com

News:

http://www.fool.com/investing/general/2013/05/14/pan-american-silver-to-pay-its-second-dividend.aspx

PAY @ $22.44

Hold: PAY July 2013 $43 Call still cooking

History:

Cost basis $43.00 per share. Premiums collected: $3.36 per share 7.63% Return in 22 months

$10,000 would have generated $758.00

actual trades:
10/22/2012 Sell To Open PAY Jan13 44 Call $0.10
06/18/2012 Sell To Open PAY Oct12 $44 Call $0.35
05/21/2012 Sell To Open PAY Jun12 50 Call $1.00

04/16/2012 Buy To Close PAY Apr12 49 Call -$5.36

01/23/2012 Sell To Open PAY Apr12 49 Call $0.40

01/22/2012 Buy To Close EXPIRED PAY JAN12 49 CALL

10/31/2011 Sell To Open PAY Jan12 49 Call $0.90

10/31/2011 Buy To Close PAY Jan12 46 Call -$1.90

10/24/2011 Sell To Open PAY Jan12 46 Call $1.10

10/22/2011 Buy To Close EXPIRED PAY Oct11 42 Call

08/23/2011 Sell To Open PAY Oct11 42 Call $0.60

08/21/2011 Buy To Close EXPIRED PAY AUG11 46

CALL

07/19/2011 Sell To Open PAY Aug11 46 Call $1.05

07/17/2011 Buy To Close EXPIRED PAY JUL11 44 CALL

06/20/2011 Sell To Open PAY Jul11 44 Call $0.75

06/17/2011 Buy To Close PAY Jun11 43 Put $0.00

06/17/2011 Buy PAY – Option Assignment $43.00

05/23/2011 Sell To Open PAY Jun11 43 Put $1.70

VeriFone Systems, Inc. designs, markets, and services electronic payment solutions that enable secure electronic payments among consumers, merchants, and financial institutions worldwide. The company provides countertop electronic payment systems that accept magnetic, smart card, and contactless/radio frequency identification cards; and support credit, debit, check, electronic benefits transfer, and various pre-paid products, as well as offers wireless system solutions. The company also provides products for the point of sale applications, which include displays, user-friendly interfaces, electronic cash registers (ECR) interfaces, durable key pads, and signature capture functionality; and contactless/near field communication (NFC) payment solutions for consumer-activated transactions using contactless cards, tokens, or NFC enabled mobile phones. In addition, it offers various products for petroleum companies, such as integrated electronic payment systems that combine card processing, fuel dispensing, and ECR functions, as well as secure payment systems for integration with petroleum pump controllers and systems. Further, the company provides server-based transaction products; secure payment hardware and software integration modules; and VeriShield Protect, a solution that encrypts and protects consumer card data. Additionally, it offers client services, including payment system consulting, deployment, on-site and telephone-based installation and training, help desk support, repairs, replacement of impaired system solutions, asset tracking, and reporting; and project management services. The company serves financial institutions, payment processors, petroleum companies, retailers, government organizations, and healthcare companies, as well as independent sales organizations. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc. in May 2010. The company is headquartered in San Jose, California.

VeriFone Systems, Inc

2099 Gateway Place Suite 600

San Jose, CA 95110

Phone: 408-232-7800 Fax: 408-232-7811

Website: http://www.verifone.com

News:

http://www.forbes.com/sites/dividendchannel/2013/05/03/verifon e-systems-moves-up-in-market-cap-rank-passing-apollo-group/?partner=yahootix

QCOR @ $37.34

Questcor Pharmaceuticals, Inc. (QCOR)

Called away @ $37.00

move to closed positions

History:

Cost basis $35.00 per share. Premiums collected: $2.00 per share Dividends:$.78

Capital Gain: $2.00 Total: $4.78

13.65% Return in 9 months

$10,000 would have generated $700.00

actual trades:

05/17/2013 Sell QCOR – Option Assignment $37.00 04/22/2013 Sell To Open QCOR May13 37 Call $0.20 04/18/2013 QCOR – QCOR QUALIFIED DIVIDEND $.025 01/22/2013 Sell To Open QCOR Apr13 $35 Call $0.55 12/21/2012 QCOR – QCOR QUALIFIED DIVIDEND $.062 12/21/2012 QCOR SUBSTITUTE DIVIDEND PAYMENT $.138 11/19/2012 Sell To Open QCOR Jan13 $35 Call $0.15 11/15/2012 QCOR – QCOR QUALIFIED DIVIDEND $.200 10/22/2012 Sell To Open QCOR Nov12 $38 Call $0.15 09/24/2012 Sell To Open QCOR Oct12 $44 Call $0.05 08/20/2012 Sell To Open QCOR Sep12 $35 Put $0.90

Questcor Pharmaceuticals, Inc., a pharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Acthar Gel, an injectable drug for the treatment of acute exacerbations of multiple sclerosis in adults; to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company s H.P. Acthar Gel also focuses on rheumatology-related conditions, including collagen diseases and rheumatic disorders. In addition, it offers Doral for the treatment of insomnia. The company sells its Acthar primarily to specialty pharmacies; and Doral to pharmaceutical wholesalers. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California.

Questcor Pharmaceuticals, Inc.

1300 North Kellogg Drive

Suite D

Anaheim, CA 92807

Phone: 714-786-4200

Fax: 714-789-4229

Website: http://www.questcor.com

TRGT @ $5.48

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $12.50 per share.

Premiums collected: $2.25 per share 18% Return in 19 months

$10,000 would have generated $1800.00

actual trades:

02/21/2012 Sell To Open TRGT May12 15 Call $0.25

11/28/2011 Sell To Open TRGT Feb12 15 Call $0.40

11/18/2011 Buy To Close TRGT Nov11 12.5 Put

11/18/2011 Buy TRGT – Option Assignment $12.50 10/23/2011 Sell to Open TRGT Nov 11 $12.50 PUT $1.60

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the nervous system. Its lead program, TC-5214, a nicotinic channel modulator, is in Phase 3 clinical trials as an adjunct treatment for major depressive disorder (MDD) and in Phase 2b clinical trial for switch monotherapy in patients with MDD. The company s novel small molecule product candidates under Phase 2 clinical development include TC-5619 for treating negative symptoms and cognitive dysfunction in schizophrenia, attention deficit/hyperactivity disorder, and Alzheimer s disease; AZD3480 as a treatment for mild to moderate Alzheimer s disease; AZD1446 as a treatment for Alzheimer s disease; and TC-6987 for the treatment of inflammatory disorders, including asthma and Type 2 diabetes. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. The company was founded in 1997 and is based in Winston-Salem, North Carolina.

Targacept, Inc.

200 East First Street

Suite 300

Winston-Salem, NC 27101-4165

Phone: 336-480-2100

Fax: 336-480-2107

Website: http://www.targacept.com

News:

http://seekingalpha.com/article/1411831-targacept-s-ceo-discusses-q1-2013-results-earnings-call-transcript?

ZIOP @ $1.67

ZIOPHARM Oncology, Inc.

Hold: January 2014 $5 Call still cooking

History:

Cost basis $3.00 per share. Premiums collected: $.25 per share 8.33% Return in 1 months

$10,000 would have generated $666.00

actual trades:

04/22/2013 Sell To Open ZIOP Jan14 $5 Call $0.05 04/19/2013 Buy ZIOP – Stock Assignment $ 3.00 03/18/2013 Sell To Open ZIOP Apr13 3 Put $0.20

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO -201), a potent bi-functional DNA alkylating agent, is under Phase III trial for the treatment of first -line metastatic soft tissue sarcoma, as well as in a pivotal Phase III trial for first-line metastatic small cell lung cancer. The company s portfolio of clinical-stage product candidates also include IL-12 DNA, which is being tested in a Phase 2 study using synthetic biology to enable controlled, local delivery of therapeutic interleukin-12; Indibulin (ZIO-301), a novel, tubulin binding agent under Phase I/II trial in metastatic breast cancer; and Darinaparsin (ZIO- 101), a novel mitochondrial- and hedgehog-targeted agent. In addition, its portfolio comprises various research-stage candidates. The company s DNA therapeutics are being developed in partnership with Intrexon Corporation through a synthetic biology platform that allows for targeted, controlled production of therapies in humans with a biologic on/off switch. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New

York, New York with operations center located in Boston, Massachusetts.

ZIOPHARM Oncology, Inc.

1180 Avenue of the Americas 20th Floor

New York, NY 10036

Phone: 646-214-0700 Fax: 646-214-0711

Website: http://www.ziopharm.com

News:

http://finance.yahoo.com/news/ziopharm-announces-presentation-promising-nonclinical-110000905.html

ZNGA @ $3.38

Hold

Take no action

There is no good option interest at this time.

History:

Cost basis $14.00 per share. Premiums collected: $2.05 per share 14.64% Return in 15 months

$10,000 would have generated $1464.00

actual trades:

03/19/2012 Sell To Open ZNGA Apr12 16 Call $0.20
03/18/2012 Buy To Close EXPIRED ZNGA MAR12 15 CALL
02/21/2012 Sell To Open ZNGA Mar12 15 Call $0.40
02/17/2012 Buy ZNGA – Option Assignment $14.00
02/17/2012 Buy To Close ZNGA Feb12 14 Put

02/06/2012Sell To Open ZNGA Feb12 14 Put$1.55

Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms. The company offers its online social games under the CityVille, Zynga Poker, FarmVille, CastleVille, FrontierVille, Mafia Wars, Word with Friends, Hidden Chronicles, Zynga Bingo, Scramble With Friends, Slingo, and Dream Heights names. Its games are available on various platforms, including Facebook and other social networks, as well as mobile platforms, such as Apple iOS and Google Android worldwide. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Zynga, Inc.

699 Eighth Street

San Francisco, CA 94103 Phone: 855-449-9642 Fax: 302-636-5454

Website: http://www.zynga.com

News:

http://www.thestreet.com/story/11926760/1/zynga-inc-class-a-stock-hold-recommendation-reiterated-znga.html?

Quote of the Month:

“When a management team with a reputation for brilliance tackles a business with a reputation for bad economics, it is the reputation of the business that remains intact. “

~ Warren Buffet

Happy New Year!

Until Next Time

Brad Lee

The Options Oracle

https://theoptionsoracle.com/

The place for safer Investments

Ask The Oracle
Webinar Sunday 8 pmESTto
explain this newsletter, or other questions
you might have.
Here is the link
http://www.anymeeting.com/MoneyMedic
1
There is no preregistration.
Summary:
Sell To Open SCTY June 2013
$35.00 Put @ Market

Covered Calls

No covered calls this month

Called away:
FMCN @ $27.00 for a 23.33%
Return
QCOR @ $37.00 for a 13.65%

Return

Past performance click here
https://theoptionsoracle.com/past-performances/
Company News

Feel free to contact me personally!

After dozens of suggestions we
decided to add this service.
Got a question or concern? Want

to learn my philosophy and why it

pays so well and consistently? Go
to “contact us”
https://theoptionsoracle.com/contacting-us/
and schedule a consultation. It is
free and now part of our service.

Military discounts are here!
Thank you for your service!

Refer a Friend
The greatest compliment you can
give me is to share me with your
friends.

Disclosure: These are my actual trades.
I am not telling you what to do, I am showing
you what I am doing.
Your subscription fee may be 100%

TAX DEDUCTIBLE if used for
educational business/investment
purposes. Check with your Licensed
Professional adviser
Company News

Auto Trading is now active!
Don’t want to be bothered doing the
trades?
Auto-trading is for you. Your account will
automatically do whatever I do.
You are still in control, you set the limits
either a dollar amount or a percentage.

Go to the main site, the Auto-trade link is
on the site
https://theoptionsoracle.com/auto-trading/
We will be doing a webinar Sunday
8 pm est to explain this newsletter.
Here is the link
http://www.anymeeting.com/MoneyMedic

Disclosure: These are my actual trades.
Your subscription fee may be 100%
TAX DEDUCTIBLE if used for
educational business/investment
purposes. Check with your Licensed
Professional adviser

Options involve risk and are not suitable for all
investors. Prior to trading options, you must
be approved for options trading and read
the Characteristics and Risks of
Standardized Options.
Copies of this document may also be obtained
from your broker, from any exchange on which
options are traded, by placing an order online,
or by contacting the Options Clearing
Corporation directly at 1 N. Wacker Dr., Suite
500, Chicago, IL 60606. (1-888-678-4667).
Brad Lee AKA “The Options Oracle” and
“The Money Medic” is an individual
investor who does not manage money for
any financial institution. You are
purchasing the list of stocks that he uses
to select options contracts he feels will
return him the highest, safest profits. Brad
is not a broker, or financial adviser. He is

a remarkable investor who has developed
a successful strategy for himself, and is
willing to share some of his magic with
you. We urge you to paper trade these
picks and learn how to develop a strategy
that is appropriate for you. Thank You.

We make no recommendations on
investment and we do not provide
financial, tax or legal advice. Content and
tools are provided for educational and
informational purposes only.

Disclaimer
Trading or investment in stocks, futures & options,

and commodity are subject to potential market risks.
You can use our materials or recommendations for
educational purposes, this is not intended as Trading
or Investment advice. We are not financial advisers.
We cannot provide any advice as to whether or not
options or our trading ideas are suitable investments
for your particular financial situation. We are in the
business of publishing our trade ideas for market
analysis only. We highly recommend that our
subscribers review their trading allocation with a
qualified registered financial adviser/planner.
Legal Disclaimer: we do not exist to render and do
not give legal, tax, economic or investment advice
and disclaims all liability for the actions or inaction
taken or not as a result of communications from or to
its members, officers, directors, employees and
contractors. Each individual should consult his/her
own counsel, accountant and other advisors as to legal, tax, economic, investment and related matters concerning any type of investments.

This email and any files transmitted with it are solely intended for the use of the addressee(s) and may contain information that is confidential and privileged. If you receive this email in error, please advise us by return email immediately. Please also disregard the contents of the email, delete it and destroy any copies immediately.